产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
产品概述
RPMI-1640是Moore等人于1967年在美国纽约州法罗市的罗斯韦尔公园纪念研究所（Roswell Park Memorial Institute, RPMI）开发出来的，RPMI是该研究所开发的一类细胞培养基，1640是培养基代号。RPMI-1640是改进型的McCoy's 5A培养基，使用碳酸氢盐缓冲系统，与大多数哺乳动物细胞培养基不同的是其典型的PH8的配方。RPMI-1640培养基最初是为淋巴细胞培养专门设计的，现在已广泛应用于各种正常细胞和癌细胞的培养，尤其是悬浮细胞的培养，是使用最为广泛的培养基之一。
青霉素-链霉素混合液通常也被称为“双抗”，是体外培养中为预防微生物污染最常用的抗生素，其中，青霉素能够干扰细菌细胞壁的合成，对革兰阳性菌特别有效；而链霉素能够与细菌核糖体30S亚单位结合，抑制细菌蛋白质的合成，对革兰氏阴性菌和革兰氏阳性菌均有效，但对革兰氏阴性菌特别有效。青霉素和链霉素联合使用可以预防绝大部分的细菌污染。
本产品含有多类细胞培养所需的氨基酸、维生素、无机盐等多种成分；但不含蛋白质、脂类或任何生长因子；故此产品需搭配血清或无血清添加物使用。
成分说明
形态 | 液体 |
浓度 | 1× |
规格 | 500mL |
pH | 7.2-7.4 |
L-谷氨酰胺 | 2 mM |
NaHCO3 | 2000 mg/L |
D-葡萄糖 | 2000 mg/L |
HEPES缓冲剂 | 无 |
青霉素G钠盐 | 100 kU/L |
硫酸链霉素 | 100 mg/L |
酚红指示剂 | 5 mg/L |
储存条件 | 2-8℃，避光 |
运输条件 | 常温 |
有效期 | 18个月 |
注意事项
1、本产品经0.1 μm过滤除菌，使用时应注意无菌操作，避免污染；
2、为保持本产品的最佳使用效果，请勿进行冻融处理；
3、本产品仅用于科研或进一步研究使用，不用于诊断和治疗。
参考文献
-
CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p (2007-02-20)
作者：Yong Xi:1.Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315040, Zhejiang, China. 13211210035@fudan.edu.cn. ; Yaxing Shen:1.Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 20032, China. ; Donglei Wu:1.School of Medicine, Jinan University, Guangzhou, 510627, Guangdong, China. ; Jingtao Zhang:1.Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China. ; Chengbin Lin:1.Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315040, Zhejiang, China. ; Lijie Wang:1.Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315040, Zhejiang, China. ; Chaoqun Yu:1.Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, 315040, Zhejiang, China. ; Bentong Yu:1.Department of Thoracic Surgery, The First Affiliated Hospital
期刊：CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p
DOI：10.1186/s12943-022-01615-8
影响因子 ：37.3
引用产品： RPMI-1640 (含双抗) 培养基
-
Bioinformatics identification of miR-514b-5p promotes NSCLC progression and induces PI3K/AKT and p38 pathways by targeting small glutamine-rich tetratricopeptide repeat-containing protein beta (2022-09-30)
作者：Lin Shi:1.Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. ; Jun Kan:1.Department of VIP Region, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. ; Lin Zhuo:1.Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. ; Siyun Wang:1.Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. ; Shaobing Chen:1.Department of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China. ; Bei Zhang:1.Department of VIP Region, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. ; Bin Ke:1.Department of VIP Region, State Key Laboratory of Oncology in South China, Collaborativ
期刊：Bioinformatics identification of miR-514b-5p promotes NSCLC progression and induces PI3K/AKT and p38 pathways by targeting small glutamine-rich tetratricopeptide repeat-containing protein beta
影响因子 ：5.6
引用产品： DMEM/F12 培养基 , RPMI-1640 (含双抗) 培养基
-
Inhibition of miR-185-3p Confers Erlotinib Resistance Through Upregulation of PFKL/MET in Lung Cancers (2007-01-20)
作者：Ke Li:1.Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. ; Xinling Zhu:1.Department of Operating Room, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. ; Conghu Yuan:1.Department of Anesthesiology, Yancheng Third People's Hospital, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng, China. ;
期刊：Inhibition of miR-185-3p Confers Erlotinib Resistance Through Upregulation of PFKL/MET in Lung Cancers
影响因子 ：5.5
引用产品： NCI-H1299 细胞 , A549 [A-549] 细胞 , RPMI-1640 (含双抗) 培养基
-
CircFAM120B Blocks the Development of Colorectal Cancer by Activating TGF-Beta Receptor II Expression via Targeting miR-645 (2007-01-20)
作者：You Yu:1.Department of General Surgery, Chongqing Bishan People's Hospital, Chongqing, China. ; Xiao Lei:1.Department of General Surgery, The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing, China. ;
期刊：CircFAM120B Blocks the Development of Colorectal Cancer by Activating TGF-Beta Receptor II Expression via Targeting miR-645
影响因子 ：5.5
引用产品： LoVo 细胞 , HCT-15 细胞 , RPMI-1640 (含双抗) 培养基
-
Circ_0109046 promotes the malignancy of endometrial carcinoma cells through the microRNA‐105/SOX9/Wnt/β‐catenin axis (2011-00-20)
作者：Yanyan Li:1.Department 1 of Gynecological Oncology, Jilin Cancer Hospital, Changchun, China. ; Jinyu Liu:1.Department 1 of Gynecological Oncology, Jilin Cancer Hospital, Changchun, China. ; Jinxia Piao:1.Department 1 of Gynecological Oncology, Jilin Cancer Hospital, Changchun, China. ; Jian Ou:1.Department of Radiotherapy of Gynecologic Oncology, Jilin Cancer Hospital, Changchun, China. ; Xiaoyan Zhu:1.Department 1 of Gynecological Oncology, Jilin Cancer Hospital, Changchun, China. ;
期刊：Circ_0109046 promotes the malignancy of endometrial carcinoma cells through the microRNA‐105/SOX9/Wnt/β‐catenin axis
DOI：10.1002/iub.2415
影响因子 ：4.6
引用产品： 人子宫内膜上皮细胞 , RPMI-1640 (含双抗) 培养基
FAQs
Q：{{item.question}}
A：
产品资料
识别码示意图
